the advisory committee to the fda now has made that recommendation. the reason i think this is so important is that we want to make sure that we impress the american public that decisions that involve their health and safety are made outside of the realm of politics, outside of the realm of self-aggrandizement and are made in essence by independent groups. so it was a very important step

well, first and foremost, creating this advisory committee, a powerful guiding coalition, assembling a committee, a group of committed folks, who are diverse in their experiences and their access to resources and not just connecting with the usual suspects, how do we get to some of the voices of people who may have some amazing ideas, but have never been invited to be part of the discussion. just sit at the table. the vision piece. we have a lot of directives and plans and programs. but what's the vision. what is it that we hope to achieve. what do we want to see happen. what's the chloroand compel -- clear and compelling statement. do we want to make sure that people are building wealth. what are those things that we want to build out. support and resources, short-term goals are going to be really important. we need to make sure that in the short-term, because this is going to have a long shelf life, what are we doing to encourage and support each other and to make sure that this doesn't get put on the shelf and forgotten about. and then, lastly, it is going to be impossible to do th

we need the advisory committee, yes. but, also, we need to address the issues of black san franciscans and how we are treated all across the board, from education, health, mass incarcerations, economic in justices, etc. i'm urging everyone on the board to address the issues of black san franciscans now. thank you very much. >> chairman: thank you. can we have the next caller, please. >> caller: hello. i name is keith. i'm the founder of "welcome back." and i'm glad this advisory committee is being formed. i'm interested in occupying the seat to help brothers re-entering the community. thank you. and i'm yielding my time. >> thank you. >>.mr. core, are there any additional callers? >> caller: yes, my name is reverend james, and i'm the secretary of the san francisco branch of the naacp. i would first like to thank mayor breed, supervisor walton, and director davis for your work. in the words of the poet, the african-american poet nicky giovanni, and she said, i really don't think life is about the i could have been; life

norton: i move the house suspend the rules and pass the bill s. 2730, drone advisory committee for the 21st century act. the speaker pro tempore: the clerk will report the title of the bill. the clerk: senate 2730 an act to accomplish and ensure an inclusive and transparent drone committee. the speaker pro tempore: pursuant to the rule, the gentlewoman from district of columbia, ms. norton, and the gentleman from illinois, mr. davis, each will control 20 minutes. the chair recognizes the gentlewoman. ms. norton: i ask unanimous consent that all members may have five legislative days to revise and extend their remarks and include ex train youse material on s. 2730. i yield myself such time as i may consume. the speaker pro tempore: without objection. the gentlewoman is recognized. ms. norton: i rise in support of the drone advisory committee for the 21st century act introduced by senator peters of michigan. the number of unmanned aircraft systems or drones in the united states airspace has grown in recent years. the growth is expected to continue as drones are deployed for more and more

that's why i am grateful we have advisory committees. the cdc's advisory committee on immunization practices has been in place for 50 years. it's a group of independent scientific experts. and they are vetted to make sure they don't have conflicts of interest. they are experts in immunology, pediatrics, vaccines that affects. we also have to have one member of the group as a member of the public. then they are surrounded by stakeholders. the group around them is implementing vaccine recommendations. their input is incredibly valuable. if we have an issue like that, we will be going to the advisory committee and saying here is the profile of these two different vaccines, please tell us how you recommend we use them. >> nancy abrams in the chat guess my follow-up question. once the advisory committee makes a recommendation for a vaccine, how does it affect the availability under medicare, medicaid, private insurance, different insurance plans that we have? how does it affect its availability to people and how they pay for it? >> these reco

last week was the pfizer vaccine, which got a pretty quick authorization after that fda advisory committee meeting, and you know, people are expecting the same here. we've looked at the data, the day th data that was released from the fda. the committee is looking at the raw data. they get granular, looking at individual patient records and ultimately making a recommendation. let me tell you a couple of things about the moderna vaccine. first of all, it's two doses, just like the pfizer vaccine. separated by 28 days. so one week extra. remember, the pfizer vaccine is separated by three weeks, moderna by four weeks, and then after an additional two weeks, that's when you're thought of the immunity when it comes to the moderna vaccine. one dose, four weeks later, another dose. two weeks after that is when you have the immunity, so a total of six weeks, and really high efficacy, close to 95% to be used in people 18 and over. we can put up the screens with both pfizer and moderna. pfizer was for people 16 and older, moderna 18 and older. the big difference is the cold storage, how cold you hav

late today a cdc advisory committee wrapped up an emergency session to see who gets first crack. two vaccines are expected to be ready by the end of the month but we now know there won't be enough to go around, so these tough decisions will answer who gets the vaccine first, who gets it next and who will have to wait for months. good evening. i'm dan ashley. >> i'm liz corey. thank you for joining us. the plan awaiting approval means that covid vaccines could be at your pharmacies in a matter of vehicles. abc7news reporter stephanie sierra is breaking it stephanie? >> reporter: the advisory committee deliberated for more than three and a half hours today before voting to recommend this distribution plan. now, if approved by the cdc, here's who gets the vaccine first. a detailed plan to distribute 40 million doses of covid vaccines, expected to vaccinate 15 to 20 million americans before the end of the year is underway. the first roll out involving 6.4 million doses could be shimmed to retail pharmacies in a couple of weeks, that is if the fda approved it. who gets it first? >> he

well, first and foremost, creating this advisory committee, a powerful guiding coalition, assembling a committee, a group of committed folks, who are diverse in their experiences and their access to resources and not just connecting with the usual suspects, how do we get to some of the voices of people who may have some amazing ideas, but have never been invited to be part of the discussion. just sit at the table. the vision piece. we have a lot of directives and plans and programs. but what's the vision. what is it that we hope to achieve. what do we want to see happen. what's the chloroand compel -- clear and compelling statement. do we want to make sure that people are building wealth. what are those things that we want to build out. support and resources, short-term goals are going to be really important. we need to make sure that in the short-term, because this is going to have a long shelf life, what are we doing to encourage and support each other and to make sure that this doesn't get put on the shelf and forgotten about. and then, lastly, it is going to be impossible to do th

cnn's jacqueline howard is monitoring that cdc advisory committee meeting. jacqueline, walk us through what we're going to see today from the committee, from the cdc, what comes next and how crucial these last elements are in this highly complicated process. >> well, these last elements are kind of the next steps in getting the covid-19 vaccine out and administered to people. so what's happening right now, the advisory committee on immunization practices is meeting to go over the covid-19 vaccine data, and the committee is going to vote on one important policy question. i have it right here. the question is this. should vaccination with the covid-19 vaccine be recommended for persons 16 years of age and older? under this emergency use authorization. so what's happening, we already heard from the fda. the fda has authorized this vaccine for emergency use. now we're going to hear from this other public agency, from the cdc, and we're going to hear their recommendation on the vaccine. this advisory committee that's meeting at this moment is the same committee th

the fda almost always goes with what the advisory committees recommend. we'll see specifically what the fda does, but i want you to hear how dr. paul offet, somebody you may now, how he framed the events of the day. >> the question is when you know enough, this appears to be our way out of this awful, awful mess. that's why i voted yes. >> i will say that there were some reservations and some discussion about some of the sub groups, certain people who maybe shouldn't take it or should take it only with certain warnings. take a look at the list there. this is going to come up again and again, i think. children under age of 16. pregnant women, breast feeding women, this was a big piano that also was discussed. pregnant women were not part of the trial. but a lot of people who were on the committee, the way they described it, is look, we don't have data to show benefit. nor do we have data to show harm. that discussion point to be continued. people who are immu knno compromised and people who have had a severe reaction to vaccines in the past are probably go

that is why i am grateful we have advisory committees. cdc's advisory committee on immunization practices are still in place for 50 years. this is a group of independent scientific experts and they are vetted to make sure they don't have a conflict of interest. they are experts in immunology, pediatrics, vaccine side effects , and they also have more members of the group, members of the public. they are surrounded by stakeholders. the group around them is the group that actually is responsible for implementing the vaccine recommendations. their input is incredibly valuable so if we have an issue like that, go into our advisory committee and say profile these two different vaccines so please tell us how you recommend we do it. chatacey abrams in the guest my follow-up question. once the advisory committee makes a recommendation for a vaccine, how does it affect its availability under medicare, medicaid, you know, private insurance, different insurance plans that we have, how does it affect its availability to people, and how will they pay

no one goes to the advisory committee they review the data and televised and then it comes to the cdc and our scientists review the data and our advisory committee reviews it in public so that everybody sees it. this may seem excessive but it's a series of checks and balances to make sure nothing falls through the cracks and it's also part of our commitment that we are going to be sure they are safe. >> as you mentioned the vaccines are undergoing review. we've received this question please explain how the vaccine doesn't change d our human dna. somebody asked me okay are there plant and animal extracts like do i want to take that. i was wondering if you could justy briefly answer that question and explain some of the fundamentals. >> i'm happy to do this at a high level. there's something about the vaccines being new and the technology people sort of find disconcerting but you will roll up your arm and get the vaccine like you get your flu vaccine then when it gets into your muscle what it does basically is gives instructions to the cells to produce something called a spike protein a

d advisory committee of the fda is meeting this thursday, december 17, to preview that vaccine. then we will anticipate the same steps will follow. the state committee will review, the advisory committee on immunization practices. if the vaccine does get emergency use authorization, then that vaccine would start flowing into our state so we -- the week of december 21. we are really excited about the potential for the moderna vaccine. there is less physical barriers with the the moderna vaccine. it is 128,000 doses of the vaccine receiving authorization for the first week, that week of december 21 in washington state, so we will be able to get that vaccine to a much broader reach across the state. gov. inslee: my final sentiments are that the enormity of this success cannot be overstated. just this past february, you could have become a very rich person betting that this was going to become available in december of 2020. it is an enormous scientific achievement. it is a gift. it is a gift of intellectual capability, entrepreneurial zeal, and a lot of hard work, a decision by the f

i served on player committees, the advisory committee on immunization practices of cdc, the fda's work on vaccines and biological products review committee, and as a member and chair of the national vaccine advisory committee. i have spent a total of 34 years on those committees. gov. inslee: could you briefly describe what the committee did, when it started its work before you reached this conclusion echo -- conclusion? >> we began 10 days ago. out whatately worked our processes would be. group with member diverse expertise. nine or 10 members have all past experience on these advisory committees, although they are independent admissions. we had access to the data, the manufacturer -- the data the manufacturer submitted, and we then, many of us observed virtually the meeting, the fda , then our committee met after each of those meetings and reviewed the data and discussed each point. so it was an exhaustive process. gov. inslee: i appreciate your work. you're not getting rich doing this, this is a volunteer group, is that right? >> totally. gov. inslee: thank you. you will get your re

we'll see what the advisory committee does with it. but it tracks with what we've heard and what pfizer presented a week ago as well. >> do you get a sense of how different or similar the moderna vaccine is from the pfizer one? >> they're very similar vaccines. they're both the messenger rna vaccines, people have heard this term a lot in the pfizer, biontech as well as the moderna one. but let me show you the specifics here. when it comes to moderna -- we'll hear more from the advisory committee -- it's two 100 micro gram doses separated by a month. it doesn't need to be kept quite as cold as the pfizer vaccine. that could be important because there's places that may not have the same cold storage capacity so this vaccine may be able to get distributed more widely. that middle line there, 94.5% efficacy. that's remarkable. it's hard to overstate that. 18 and older. pfizer was 16 and older in terms of who might take this vaccine and we know the moderna one is still being considered for authorization, not there yet. let me contrast that

i'm now told the advisory committee go to the full fda.hey will presumably approve it, and then the final step in all of this before it's released to the public will be on sunday when the centers for disease control and prevention is expect to vote and presumably approve it. but walk us through the exact process. >> actually, once the fda gets approved the vaccine can get distributed. the committee is more advising who should get it first. and the phase 1a as it's called it pretty straightferr forward. and the nursing home population is particularly important because it's been about 40% of all of the deaths. and getting both the residents and staff of nursing homes vaccinated as quickly as possible and going to be the single highest impact a population in the vaccination program. and i would hope every state, every community is making sure they have a way to get those populations vaccinated as quickly as possible because really if we would first doses in the next few weeks, second dose three, four weeks later you could get most of the nurs

i'm asking the controller who i spoke with this morning, to reconvene the technical advisory committee in january of this year so we can begin the conversation. i know that supervisor peskin was deeply involved in that at the time. i believe that the time is important because of the economy, because of the recession. weapon want to en-- weapon want to ensure whatever type of housing, market rate, inclusionary, that we're doing it, we're doing it in the context where we are with the economy. the second item, it was something that was brought to me by my designee to the city youth commission. she's also a youth advocate in district 11, is urging us and i'm very interested in this, it's very important to me. under the guise of 2021, i have reached out to school board member commissioner lamb as well as commissioner collin who are excite to work with us on this. i'm going to read a portion of the resolution. essentially it's something that was introduced last thursday by commissioner jones of human rights commission. given the context where we are in terms of the school year and so many ch

then the fda takes it as advice because these truly are advisory committees. so what dr. hahn was saying, what he told me personally a couple of weeks ago, is the fda is going to look at this information, look at this advice very closely and they're going to make sure this vaccine is safe and effective regardless of outside pressure before they move forward with that authorization because they want to make sure that once they get the emergency use authorization, that the public understands it's safe. they're also making sure these meetings are open to the public, the information is transparent. we got this information a few days ago, the same information the vrbpac is using to make their decision. the fda will answer those questions a lot of people are asking about the vaccine, about certain groups, about the potential for side effects, we've heard about the allergy side effects that have happened, they want more information on that as well. and then the vrbpac will give them that information, give them that advice, and take a vote at the end of the day saying, yes, we do

fda advisory committees are just that. advisory in nature. 's important to note that the advice that the fda receives from the committee does not represent the position of the fda, rather the fda weighs the advice it receives when taking actions on medical products. fda ultimately makes the final decisions on all matters that come before the committee. also, expectations for today's meeting we organized the agenda topics slightly differently than last week's meeting to allow the committee members to have time for robust discussion of the questions before them. we invite the public and the committee to review the presentations and recording of the december 10th meeting for more information on covid 19 epidemiology, vaccine safety, and effectiveness monitoring and operational zbrooix plan as those will not be covered in-depth today as they were at the last meeting. as we begin today's proceedings, i want to take the opportunity to thank you all, including all the advisory committee members for the insights they'll provide and, also, thank the fd

i am vice chair of the market advisory committee and hayes valley neighborhood association employment committee. calling with in youic support for the im provements. connects schools, parks and housing. during this pandemic things have gotten worse because buchanan has become a cut through north south route. cars can exit the freeway, come up and fly up buchanan. we a lot of stop signs there. this is very important to address this. long-term the open cell issue is a chronic congestion problem that needs addressed along the entire length of the corridor. this is particularly burdened and causes a hostile situation on the streets. this is a very tent rich part of the city. the very dense part of the city with a lot of car-free households or car-lighthouse holds doing the right thing but putting up with the chronic congestion. this neighborhood is what is needed and it is mitigation from the previous s.f.c.t.a. study of octavia boulevard. i thank dean preston for moving this forward and please support the project. thank you. >> there are no more callers. >> public comment is closed. i su

our state advisory committee looked at it. ours follows pretty closely with the cdc recommendation is. our definition of essential workers follows pretty closely what the cdc says. people who are incarcerated, that the risk is significantly higher in congregate care facilities. in our persons will get a vaccine just as other people reach that age spot. but then, it comes in in the , and ipart of phase 2 will let dr. cohen address that even more. thanks, governor. two things to point out. in the phases, you need to make the distinction between front-line east central workers -- frontline essential workers. that is defined by the cdc. you can find that on our website now. this information is there. you can know what categories of folks. firefighters, police officers, k-12 teachers, those who are working in childcare, u.s. postal service. those are the categories in frontline essential workers. there is another bucket of workers captured in phase two, also defined by the cdc. i would encourage folks to look for the details. as th

using the guidance from independent federal and state advisory committees north carolina continues towork to get this vaccine to people as quickly as possible. the vaccine along with more funding from the federal government has provided a glimmer of hope at the end of a long year and when we rang in 2020 we did not expect to be closing it out in the grips of the global pandemic but here we are. we have to seize our resolve and make it last. we've learned a great deal about how to combat covid-19 cents of the virus emerged. but we have also learned a lot about our communities and ourselves. but live up to our ideals by doing what we know works, wear a mask, practice social distancing, avoiding gatherings where the virus can be spread easily and remember, this new year's eve we still have a modified stay-at-home order in place from 10:00 p.m. until 5:0. our collective new year's resolution should be keeping each other safe in 2021. most north carolinians work hard to care for one another in 2020 and let's continue those efforts and keep that spirit going as we turned the page on a new y

bicycle advisory committee to the full board with recommendations. supervisor stefani. >> aye. >> supervisor mar. >> aye. >> chair ronen. >> aye. >> motion passes without objection. >> thank you. >> thank you, mark. appreciate you. thank you for your work. >> mr. clerk, can you please call item number 3. >> clerk: item number 3 is a hearing to consider appointing one member term ending august 1st, 2021 to the south of market community planning advisory committee. >> thank you. and we have one appointment, mary claire to seat 2 nominated by supervisor haney. is mary here with us today? >> hi. >> hi, how are you? >> i'm good. good morning. >> good morning. is there any information that you would like to share with us about your work and why you are a playing for this position? >> i'll give a quick run down and who i am and why i want to serve on this -- >> i'm here today to ask for your support in appointing me to serve on the soma planning (inaudible). i was born and raised in the tenderloin and i moved back and fourth between here and soma. i'm in sc

we're an advisory committee. so that is the advice. the fda is going to quickly move through to make sure they agree. the cdc is meeting today and then they're meeting again on sunday. so my sense is what's going to happen today is the cdc is going to discuss what they think about whether or not they would recommend this vaccine, but they can't really recommend it until the fda has approved it. and then i think they're going to discuss it today. the fda is probably going to approve it by sunday. >> at what point does it get triggered that the sort of boxes he you he go on trucks. >> i think the minute they moved forward with we can go ahead with the authorization, that will happen. it looks like the advisory committee for the immunization practice, the cdc is going to vote on this on sunday. so i think monday is the day. >> so they don't have to wait for that cd can c meeting on sunday. that's good to know. i want to talk about this advisory panel meeting because there were divisions frankly on the question of whether the benefits outw

we held a public advisory committee on thursday about the pfizer biontech application. the advisory committee consists of experts who reviewed clinical data from pfizer and biontech submissions and provided their own recommendations related to the data concerning the safety and effectiveness of the product. agreed that the vaccine's benefits outweigh its risks. we have also made clear through two guidance documents, the information a developer should provide to us for their covid-19 vaccine, helping americans understand what data we would be looking at during our review process. yesterday, we have posted important information to help health care providers understand the benefits, risks, and proper use of this vaccine, including fact sheets for health care providers and vaccine recipients. instructions for use, the letter of authorization to the requester, which spelled out the conditions under which use of the product is authorized. we also intended to post the decision memorandum, which outlines the basis of our decision. all of this information helps the public unders

arranges the advisory committee meetings to go the way they plan the decision should go in almost every case so yes i think within a very few days deal they will approve this flies or vaccine as the 1st u.s. covert vaccine there are up to 100000000 doses that there's 2 doses. so that's up to 50000000 people could conceivably get it although many people have said they don't want to they don't want to be the 1st ones why should the beginning . what about those warnings coming from the u.k. the people who have severe out as you should avoid taking that vaccine i mean with other vaccines as far as i know there are also warnings that come with warning labels that people with certain conditions perhaps immunocompromised people shouldn't take them do you think we should be concerned about these these this results coming out of the u k. yes at the advisory committee meeting today it was said that people with severe allergies will be advised not to take it i think it's a risk for all the axioms anaphylaxis which is what happened to 2 people in the u.k. on the 1st day the vaccines were given. the

the cdc advisory committee expected to vote soon on the pfizer vaccine. we have dr.out the developments. that's next. a must in your medicine cabinet! less sick days! cold coming on? zicam® is clinically proven to shorten colds! highly recommend it! zifans love zicam's unique zinc formula. it shortens colds! zicam zinc that cold! been there, done that. twice your cousin. from boston. karen, i'm just gonna say what everyone here is thinking. you look smokin. total smokeshow. and they never did find his finger. they had to close the pool for like an hour. ♪ i brought a date. name's sam. dig in. love is like boston lager. rich, complex and it's over too soon. right, chrissy? oh my god. ♪ robinwithout the commission fees. so, you can start investing today wherever you are - even hanging with your dog. so, what are you waiting for? download now and get your first stock on us. robinhood. >>> breaking news. the cdc advisory committee is moments away from voting on the recommendation from the pfizer biontech vaccine. that prepared with the fda emergency use authorization thi

moments ago, the centers for disease control and prevention advisory committee on immunization practice voted to recommend the pfizer and biontech vaccine for people 16 and older. this is the second to last step after the fda issued the emergency use authorization for this coronavirus vaccine in record time. it is the fastest vaccine has ever been developed. remember in april? medical experts said 18 months was optimistic. a blink in vaccine years. here we are in the 12th month of the year that has really turned all of our lives upside down with a safe, effective vaccine from pfizer and biontech. tomorrow is when the shipping begins, we're told with the doses headed to the most vulnerable citizens. it is months before the general public can roll up their sleeves, this could not come at a more crucial time. yesterday, more than 108,000 people are hospitalized. another 3,300 lives lost to the coronavirus. we're at the point where it is a mass casualty event day after day. some communities are now feeling the impact of the post-thanksgiving surge. officials say the upcoming christmas holid

, an independent advisory committee called the vaccine and related products advisory committee or vrpact yesterday looked at the data and said this is safe, and this is effective. so now, the fda will, i'm sure, soon make a determination and essentially grant what's called an emergency use authorization to allow the actual distribution of the vaccines to people so that it actually goes into someone's arm. so the thing we need to make sure the american public appreciates is that these determinations about safety and efficacy were done independently and transparently so that we see the data, we know about it. there's nothing secret about it. >> when you look at what we're hearing from people around the country, there is skepticism. and we see it also breaking along certain demographic groups. for example, about 60% of white americans intend to get it. the numbers are lower for black americans. and the myths that are out there, while we don't want to reinforce them, i want to give you a chance to address this. you have folks concerned, quote, that this was rushed. that it could give you be

so, that will be part of the conversation, the advisory committee will discuss this preliminary phase 1-c plan. they'll make adjustments, we'll make accommodations, because we're getting a lot of people lobbying, a lot of people providing insight and developmental disabilities individuals, those are impactful subpopulations and people are coming in making sure that we don't forget critical populations in the state. again, all with an eye on equity, all an eye on region alec which the, not just racial and ethnic. socioeconomics, always considered as well. that's the plan for the vaccinate-all discussion this wednesday. and, again, hope you tune in. if i've confused you, you can have more simplified version of l this this wednesday on the covid19.ca.gov website. let's talk more now about what's been done to date in terms of the vaccines that have arrived in this state, and the vaccines that have actually been distributed. so let me update you on the current status of moderna. the doses to california. we anticipate by the end of this week that we'll receive all 904,900 doses of the moder

the advisory committee to the fda now has made that recommendation.eason i think this is so important is that we want to make sure that we impress the american public that decisions that involve their health and safety are made outside of the realm of politics, outside of the realm of self-aggrandizement and are made in essence by independent groups. so it was a very important step this evening, around 5:00 or so, when the decision was made. now the fda will take under consideration that recommendation and will very likely act on it quite soon. >> okay. and, look, you you're now at about 60/30 of people in favor of taking the virus, which is an improvement over what it had been. the more information that comes out, the less trump has to do with it, the better it may get. why are things so bad right now? >> well, it's a conflation of things, chris, that you and i have spoken about in the past. we have a very high baseline of infections, over 200,000 a day. we now have reached 3,000 deaths yesterday. we have over 100,000 hospitalizations. the baseline w

just hours ago, a vaccine advisory committee comprised of top doctors and health officials across the country voted on a distribution plan that is awaiting approval from the cdc. stephanie sierra is live breaking down the guidance and the controversy that comes with it. >> that's right, dan. 15 committee members of the acip, the advisory committee on immunization practices deliberated for more than three and a half hours before voting to recommend this distribution plan. if approved by the cdc, here is exactly who gets the vaccine first. a detailed plan to distribute 40 million doses of covid vaccines expected to vaccinate 15 to 20 million americans before the end of the year is underway. the first rollout involving 6.4 million doses could be shipped to retail farm sees in a couple of weeks. that's if the fda approves emergency use authorization for pfizer or moderna. who gets it first? >> health care workers are at the top of the list including health care workers who work in nursing homes where the most deaths have occurred from this virus. >> reporter: members of the advisory commi

has been completed and we have this vaccine advisory committee working with just your mission advisorymittee. completed on 1-a the website. the next public meeting, meaning we want you to take a look, it is open to the public on wednesday. website and learn about when these meetings are conducted. you get real-time information as quick as any of us get. they have done a magnificent job, the advisory committee. the next meeting for the next allocation, sob, you get a sense of where we are going, that is wednesday. approve the pfizer vaccine as early as the 10th and approval toderna occur week or so later. that gives you a sense of the cadence of the vaccination. we are getting into december now, first week of december, and i expect -- i really believe this, we will start to see good news and numbers will significantly improve just -- over the weeks and months in terms of vaccinations. planning a assumptions -- planning assumptions for the 327,000 doses for pfizer's, but then you have moderna and all the other distributors of vaccines stacking behind them. we are working on an assumption

i plan to get the vaccine. >> reporter: the acting a chair of the independent advisory committee says the vaccine needed to be at least 50% effective for it to receive the committee's recommendation. >> this vaccine is in excess of 90%. that's almost a dream scenario. >> did you vote yes or no? >> i voted yes enthusiastically. >> reporter: right now, hospitals nationwide are preparing to receive first shipments and that can happen as early as this weekend. this is the freezer inside of los angeles' cedar sigh my hospital where the vaccine will be kept. >> once we take the vaccine out of the freezer we have five days in the refrigerator. >> reporter: that's the chief pharmacy officer here. she has reviewed vaccine data and says reports about allergic reactions in united kingdom don't raise alarm bells. >> allergic reactions are something that occur with everything. they aren't as concerning as getting covid. the focus is on keeping us safe. >> reporter: fda does want pfizer to do more studies about the allergic reactions. it will come with a warning for people with allergic reactions.

i know firsthand the importance of your advisory committee work. thank you. >> the next speaker is ms. lynda dee. >> hi, thank you. i'm from baltimore in the aids treatment i was the coalition. i have no conflicts of interest. one important ethical issue involving maintaining participants in the placebo arm after eua has been discussed. i think it is very reassuring that the sponsor is proposing the placebo participants be permitted to decide whether to remain on the placebo or receive the vaccine within the study at the appropriate time. the crossover design will hopefully ensure that the study will not crash. crossovers are nobody's favorite, but an unblinded crossover is probably much more feasible here. lay people have no understanding of the nuances discussed today. acceptable designs that will confirm initial eua data and protect current participants and suspicious potential future participants promoting public trust are essential. i do have a few important remaining concerns. the study for pregnant women should be much further along by now.

shingrix protects. >>> these are live pictures of the fda's advisory committee meeting.ely in these times on pfizer's covid-19 vaccine. the u.s. could have its first authorized vaccine for the coronavirus in just hours. the decision to take place in that meeting you're watching right now. >> let's get to our colleague alexandra field she joins us from new jersey. you are at a facility that is getting ready to be a vaccine distribute site. what's happening? >> reporter: exactly, poppy. look, this is actually a gym at a nursing school, it's just like a lot of sites all over the country that are being converted for this huge undertaking, conducting a mass vaccination. this is a site that would be used for the general public once the vaccine is available for the general public. it's a site that's also being administered by holy name medical center but they say when they receive the first doses of the vaccine those of course as we've been reporting will go to the front line workers. they are waiting along with the rest of us for that emergency use authorization from the fda.

less with the community vaccine advisory committee to discuss the next phase of vexing distribution. i will remind you we are in the current phase. phase 1a, which is prioritizing. purchasing skilled nursing facilities and congregate care facilities and the healthcare workforce. they put out to that pan and we are implementing that plan. plan 1b and plan once he are very hotly anticipated, forgive the phrase. everyone is wondering where they stack in terms of that plan. they are not healthcare workers, but they are not in a congregant facility or skilled nursing facility and the like. then plan 1c. there was a very public forum and i remind you, we have guidelines work group that does the technical work. 16 members, and then you have the 60+ member advisory committee. a community advisory committee that has a public dialogue, discussing the merits and demerits of that drafting work group plan. that is, again, on our covid-19 website. you can watch the next cohort to be discussed. you can watch the work group presentation and get a sense of the dynamic, the dialectic in terms of that

>> the krvshgs tvshgs krvshgs's advisory committee made that vote last night to basically green light the plan of action of getting a couple of groups ready to go in front of the line when this vaccine maybe one or the two that are on the table right now in front of the fda get approved. those are the front line healthcare workers and those living in long-term care facilities. the panel voted 13-1 to recommend the two critical groups. the group gave emergency authorization to pfizer something health and human services secretary said should be reassuring for the americans as the fda works through its own process to ensure that the vaccine is safe and effective for youth care. >> they have a very detailed approach. they look under the hood. they're going to look at all of the data to make sure that it appears to be as good as it appears and we'll have that meeting of the advisory committee on december 10. >> hours ago, the cdc released guidance on quarantine times to those who may have been exposed and tested negative. they're moving the goal post from 14 days to 7 days and 10 days for

bicycle advisory committee to the full board with recommendations. supervisor stefani. >> aye. >> supervisor mar. >> aye. >> chair ronen. >> aye. >> motion passes without objection. >> thank you. >> thank you, mark. appreciate you. thank you for your work. >> mr. clerk, can you please call item number 3. >> clerk: item number 3 is a hearing to consider appointing one member term ending august 1st, 2021 to the south of market community planning advisory committee. >> thank you. and we have one appointment, mary claire to seat 2 nominated by supervisor haney. is mary here with us today? >> hi. >> hi, how are you? >> i'm good. good morning. >> good morning. is there any information that you would like to share with us about your work and why you are a playing for this position? >> i'll give a quick run down and who i am and why i want to serve on this -- >> i'm here today to ask for your support in appointing me to serve on the soma planning (inaudible). i was born and raised in the tenderloin and i moved back and fourth between here and soma. i'm in sc

the fact that the fda's advisory committee, the vaccine and related biological products advisory committee, or vrpac, the one that met today and voted to recommend the fda to grant the eua, that's really important, chris, because what it shows is the process that we have here in the united states is decisions and recommendations are made by independent bodies just the way the data and safety monitoring board looked at the data a while ago and said it looks good, let's examine the data and see if we can get an eua. the advisory committee to the fda now has made that recommendation. the reason i think this is so important is that we want to make sure that we impress the american public that decisions that involve their health and safety are made outside of the realm of politics, outside of the realm of self-aggrandizement and are made in essence by independent groups. so it was a very important step this evening late -- around 5:00 or so when the decision was made. now the fda will take under consideration that recommendation and will very likely act on it quite soon. >> okay. and look, you'

fda advisory committees are just that. advisory in nature. it's important to note that the advice that the fda receives from the committee does not represent the position of the fda, rather, the fda weighs the advice it receives when taking actions on medical products. fda ultimately makes the final decisions on all matters that come before the committee. also, to set expectations, for today's meeting, we organized the agenda topics slightly differently than last week's meeting to allow the committee members to have sufficient time for robust discussion of the questions before them. we invite the public and the committee to review the presentations and recording of the december 10th meeting for more information on covid 19 epidemiology, vaccine safety, and effectiveness monitoring and operational distribution plans, as those will not be covered in-depth today as they were at the last meeting. as we begin today's proceedings, i want to take the opportunity to thank you all, including all the advisory committee members for the insights they'll p

the advisory committee meeting just began minutes ago. this is a live picture of that meeting. the panel expected to vote on emergency use authorization this morning and the fda will give final approval shortly after that. before that approval, there's that side effect that is likely to be the topic of discussion. we told you about this yesterday morning. out of thousands in the uk who received the shot, two people, both health care workers, had allergic reactions and recovered. research shows that the vaccine is 95% effective. when the fda signs off, 2.9 million doses will be sent out across the country within 24 hours. >> there's much more to learn here, we're operating under difficult circumstances, but under the conditions we should feel good about where we are right now. >> even with the vaccine, the latest report from the covid task force paints a grim picture. it warns that the vaccine will not prevent viral spread, hospitalizations or deaths until late spring. >> all right. thank you. >>> we're learning how many doses california and bay area counties will be getting. th

the advisory committee listened to results from pfizer's vaccine trial and took public comments whether to recommend emergency use authorization. this hearing is taking place while fedex and u.p.s. trucks are ready to transport the vaccines to hospitals across the country. many expressed praise for pfizer and a covid-19 vaccine, some raised concerns. >> i think i got a real vaccine and not a placebo because of mild adverse effects such as pain and fever. after reporting the side effects, i was called by the doctors and researchers to see if i was okay. and i was. nothing felt rushed and i never felt like a guinea pig. >> it is one big human experiment. the only ones that have 100% immunity in this will be the pharmaceutical companies. they have no legal liability should something go wrong. >> reporter: they are making sure the benefits and risks are told to the public. the committee is expected to take this critical vote later today around 3:30. reporting live, i'm sharon katsuda, nbc bay area news. >> share, thank you. >>> there are still companies working to come you with a vaccine. m